Abstract
PURPOSE OF REVIEW: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.
RECENT FINDINGS: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.
SUMMARY: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 568-573 |
| Number of pages | 6 |
| Journal | Current Opinion in Urology |
| Volume | 35 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 01 Sept 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Humans
- Prostatic Neoplasms/radiotherapy
- Male
- Heavy Ion Radiotherapy/methods
- Radiotherapy Dosage
- Treatment Outcome
- Risk Factors
- Risk Assessment
Fingerprint
Dive into the research topics of 'Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver